Comments
Loading...
Kyorin Pharmaceutical Analyst Ratings and Price Targets | OTC:KYRNF | Benzinga
Kyorin Pharmaceutical Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Kyorin Pharmaceutical Corp from these most-recent analyst ratings.
Analyst Ratings for Kyorin Pharmaceutical
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Kyorin Pharmaceutical (KYRNF) stock?
There is no price target for Kyorin Pharmaceutical
What is the most recent analyst rating for Kyorin Pharmaceutical (KYRNF)?
There is no analyst for Kyorin Pharmaceutical
When was the last upgrade for Kyorin Pharmaceutical (KYRNF)?
There is no last upgrade for Kyorin Pharmaceutical
When was the last downgrade for Kyorin Pharmaceutical (KYRNF)?
There is no last downgrade for Kyorin Pharmaceutical.
When is the next analyst rating going to be posted or updated for Kyorin Pharmaceutical (KYRNF)?
There is no next analyst rating for Kyorin Pharmaceutical.
Is the Analyst Rating Kyorin Pharmaceutical (KYRNF) correct?
There is no next analyst rating for Kyorin Pharmaceutical.
Browse analyst ratings and price targets on all stocks.